A clinical trial testing a 1-week schedule of whole breast radiotherapy against a 3-week schedule

Conditions

Breast cancer Cancer Malignant neoplasm of breast

Brunt AM, Cafferty FH, Kirby AM, Patel J, Sydenham MA, Haviland JS, Griffin S, Chivardi C, Fleming H, Coles CE, Bloomfield DJ, Chan C, Cleator S, Goodman A, Griffin CL, Kirwan CC, Nabi Z, Sawyer E, Somaiah N, Syndikus I, Venables K, Wheatley DA, Yarnold JR, Bliss JM.

2026-05-14

10.1016/s1470-2045(26)00076-8

Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study.

Brunt AM, Cafferty FH, Wheatley D, Sydenham MA, Kirby AM, Coles CE, Patel J, Alhasso A, Chan C, Cleator S, Fleming H, Gahir D, Goodman A, Griffin C, Haviland JS, Kirwan C, Nabi Z, Poole K, Sawyer E, Sinclair J, Somaiah N, Syndikus I, Venables K, Yarnold J, Bliss JM.

2025-05-043 citations

10.1016/j.radonc.2025.110915

One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT

Adrian Murray Brunt, Joanne Haviland, Duncan Wheatley, Mark Sydenham, David Bloomfield et al. (24 authors)

Health Technology Assessment2023-11-0118 citations

10.3310/wwbf1044

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan CC, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Bliss JM, Yarnold JR, FAST-Forward Trial Management Group.

2020-04-28720 citations

10.1016/s0140-6736(20)30932-6

Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository.

Kilburn LS, Aresu M, Banerji J, Barrett-Lee P, Ellis P, Bliss JM.

2017-11-2311 citations

10.1186/s13063-017-2308-6

Interventions

Patients will be randomised equally between a standard 3-week schedule and two 1 week test schedules of whole breast radiotherapy Whole breast radiotherapy schedules: Standard group - 40 Gy in 15 fra

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age more than or equal to 18 years 2. Female or male 3. Invasive carcinoma of the breast 4. Breast conservation surgery or mastectomy (reconstruction allowed but not with implant. Tissue expanders with distant metal ports are allowed) 5. Axillary staging and/or dissection 6. Complete microscopic excision of primary tumour 7. Stage pT1-3 pN0-1 M0 disease 8. Written informed consent 9. Able to comply with follow up Concurrent trastuzumab and hormone therapy is allowed

Exclusion criteria

Exclusion criteria: 1. Past history of malignancy except basal cell skin cancer and cervical intraepithelial neoplasia (CIN) or non-breast malignancy allowed if treated with curative intent and at least 5 years disease free 2. Contralateral breast cancer, including ductal carcinoma in-situ (DCIS), irrespective of date of diagnosis 3. Breast reconstruction using implants 4. Concurrent cytotoxic chemotherapy (sequential neoadjuvant or adjuvant cytotoxic therapy allowed) 5. Radiotherapy to any regional lymph node areas (excepting lower axilla included in standard tangential fields to breast/chest wall)

Design outcomes

Primary

Measure	Time frame
Ipsilateral local tumour control: Will be reported at the annual follow up visits. The tests will be performed when the need arises i.e. when the patient feels unwell or reports another lump etc. The tests will be carried out as routine clinical examinations i.e. X rays, computerised tomography (CT) scans, magnetic resonance imaging (MRI), ultrasound.	—

Secondary

Measure	Time frame
1. Early and late adverse effects in normal tissues 2. Quality of life at baseline, 6, months and 2, 5 and 10 years post randomisation 3. Contralateral primary tumours, regional and distant metastases 4. Survival	—

Countries

England, United Kingdom

Outcome results

None listed